` CSBTF (Kuros Biosciences AG) vs S&P 500 Comparison - Alpha Spread

CSBTF
vs
S&P 500

Over the past 12 months, CSBTF has significantly outperformed S&P 500, delivering a return of +70% compared to the S&P 500's +14% growth.

Stocks Performance
CSBTF vs S&P 500

Loading
CSBTF
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CSBTF vs S&P 500

Loading
CSBTF
S&P 500
Difference
www.alphaspread.com

Performance By Year
CSBTF vs S&P 500

Loading
CSBTF
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Kuros Biosciences AG vs Peers

S&P 500
CSBTF
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Kuros Biosciences AG
Glance View

Market Cap
1.5B USD
Industry
Biotechnology

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

CSBTF Intrinsic Value
51.15 USD
Undervaluation 25%
Intrinsic Value
Price
Back to Top